GCG and obesity disorder: Semaglutide 2.4 mg (a GLP-1) has demonstrated an average weight loss of 15% weight loss over 68 weeks (7) and now includes an indication for the prevention of major adverse cardiovascular events in people with overweight or obesity without diabetes (8).